100 Years of insulin: Lifesaver, immune target, and potential remedy for prevention

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

  • Anette-Gabriele Ziegler - , Helmholtz Zentrum München - German Research Center for Environmental Health, German Center for Diabetes Research (DZD), Technical University of Munich (Author)
  • Thomas Danne - , Children's Hospital Auf der Bult (Author)
  • Carolin Daniel - , Helmholtz Zentrum München - German Research Center for Environmental Health, German Center for Diabetes Research (DZD), Ludwig Maximilian University of Munich (Author)
  • Ezio Bonifacio - , Chair of Preclinical stem cell therapy and diabetes, Paul Langerhans Institute Dresden (PLID) of the Helmholtz Center Munich (Author)

Abstract

In this review, we bring our personal experiences to showcase insulin from its breakthrough discovery as a life-saving drug 100 years ago to its uncovering as the autoantigen and potential cause of type 1 diabetes and eventually as an opportunity to prevent autoimmune diabetes. The work covers the birth of insulin to treat patients, which is now 100 years ago; the development of human insulin, insulin analogs, devices, and the way into automated insulin delivery; the realization that insulin is the primary autoimmune target of type 1 diabetes in children; novel approaches of immunotherapy using insulin for immune tolerance induction; the possible limitations of insulin immunotherapy; and an outlook on how modern vaccines could remove the need for another 100 years of insulin therapy.

Details

Original languageEnglish
Pages (from-to)1120-1137
Number of pages18
JournalMED
Volume2
Issue number10
Publication statusPublished - 8 Oct 2021
Peer-reviewedYes

External IDs

Scopus 85116486857
ORCID /0000-0002-8704-4713/work/141544117
PubMed 34993499

Keywords

Research priority areas of TU Dresden

Sustainable Development Goals

Library keywords